Smith Financial Statements From 2010 to 2025
| SNNUF Stock | USD 12.57 0.01 0.08% |
Check Smith Nephew financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Smith Nephew's main balance sheet or income statement drivers, such as , as well as many indicators such as . Smith financial statements analysis is a perfect complement when working with Smith Nephew Valuation or Volatility modules.
Smith |
Smith Nephew plc Company Return On Equity Analysis
Smith Nephew's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Smith Nephew Return On Equity | 0.0925 |
Most of Smith Nephew's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Smith Nephew plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Smith Nephew plc has a Return On Equity of 0.0925. This is 100.39% lower than that of the Healthcare sector and 101.06% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 129.84% lower than that of the firm.
Smith Nephew plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Smith Nephew's current stock value. Our valuation model uses many indicators to compare Smith Nephew value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Smith Nephew competition to find correlations between indicators driving Smith Nephew's intrinsic value. More Info.Smith Nephew plc is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Smith Nephew plc is roughly 2.18 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Smith Nephew's earnings, one of the primary drivers of an investment's value.About Smith Nephew Financial Statements
Smith Nephew stakeholders use historical fundamental indicators, such as Smith Nephew's revenue or net income, to determine how well the company is positioned to perform in the future. Although Smith Nephew investors may analyze each financial statement separately, they are all interrelated. For example, changes in Smith Nephew's assets and liabilities are reflected in the revenues and expenses on Smith Nephew's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Smith Nephew plc. Please read more on our technical analysis and fundamental analysis pages.
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 18000 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Smith Pink Sheet
Smith Nephew financial ratios help investors to determine whether Smith Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Smith with respect to the benefits of owning Smith Nephew security.